<img height="1" width="1" src="https://www.facebook.com/tr?id=914352225269004&amp;ev=PageView &amp;noscript=1">
HubSpot Video
New Sleep Disturbance Clinical Trial

If you dream of better sleep...

📢 We are investigating a potential new treatment for sleep disturbances

In order to be considered to take part in the study, you’ll need to meet all of the following:

✔️ You are aged 18 to 75 (inclusive)
✔️ Your BMI (Body Mass Index) is not greater than 35
✔️ You are experiencing a disturbed sleeping pattern

If that sounds like you, we would like to invite you to take part in our latest study investigating a potential treatment.

Click here or scroll down to learn about this study's inclusion criteria ⬇️

👉 Express your interest by filling out the registration form

By signing up to Evrima Connect, you consent to Evrima Technologies' Terms of Service and Privacy Policy.

If you take part in the research study you will receive:

Reimbursement of costs

For out-of-pocket expenses, such as travel and parking.

Free study-related medical care

You may gain access to new research treatments, before they are widely available.

No overnight stays!

All study visits are out-patient only.

🏥 Study Guide

Who can take part in this study?

In order to be eligible to participate in the study, you must meet all of the following:

  • You are aged 18 to 75 years old
  • You have been experiencing one or more of the following sleep disturbances, for at least a month:
    • Difficulty falling asleep
    • Difficulty maintaining sleep
    • Waking up earlier than you would like

Who is unable to take part in this study?

Unfortunately, if you meet any of the following, this study is not the right fit for you:

  • Anyone who has a history of significant cardiac disease
  • Anyone who is receiving prescribed or over-the-counter sleep medication or sleep aids

How long will the study take?

If you agree to take part, and the study is suitable for you, your participation in the study is expected to last up to 51 days. This includes:

  • A screening period of 11 days
  • An initial measurement period of 3 days
  • A treatment period of 30 days
  • A one-week follow-up period

What is the purpose of this study?

This study aims to test a potential new treatment for sleep disturbance using Satipharm CBD (Cannabidiol) capsules. CBD use has been shown to be safe and tolerable in animal and human studies on insomnia (difficulty sleeping).

The study drug does not contain any THC, therefore is not intoxicating and will not cause you to experience any THC related side effects.

Currently, CBD is only available to people with a confirmed diagnosis and a prescription from a doctor. Results from this study may allow for this therapy to become available as an over-the-counter medication.

What is Sleep Disturbance?

The term “sleep disturbance” means difficulty in initiating and maintaining proper sleep. It refers to conditions that affect sleep quality, timing, or duration and they impact a person’s ability to properly function while they are awake. These disorders may also contribute to other physical and mental issues.

Where is my nearest study site?

Here is a list of all of the sites who are currently recruiting for this study:

  • ACT, Bruce, Paratus Clinical Research Canberra
  • NSW, Blacktown, Paratus Clinical Research Western Sydney
  • NSW, Kanwal, Paratus Clinical Research Central Coast
  • QLD, Albion, Paratus Clinical Research Brisbane
  • SA, Adelaide, CMAX Clinical Research
  • WA, Nedlands, Captain Stirling Medical Centre

What if I have other questions about the study?

We are here for you! Click or tap this button to send an email to our Patient Experience team: